Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback